TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02760940
Drug: oral liposomal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
Study: NCT01514019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule(Capsules filled up with lactose)
Study: NCT01962441
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet administered orally once daily
Study: NCT00941655
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes.
Study: NCT00609167
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m\^2 PO days 1, 8, 15 \& 22
Study: NCT00088140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00404417
Drug: Botulinum Toxin A / Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin A at first injection / Placebo at second injection
Study: NCT00404417
Drug: Botulinum Toxin A / Botulinum Toxin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
Study: NCT00404417
Drug: Placebo / Botulinum Toxin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at first injection / Botulinum Toxin A at second injection
Study: NCT00404417
Drug: Placebo / Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at first injection / Placebo at second injection
Study: NCT00327106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
Study: NCT01167088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02731885
Drug: ABX464 Single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Study: NCT01504256
Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)
Study: NCT01504256
Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)
Study: NCT03268733
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet 5 mg
Study: NCT02513186
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT00659893
Drug: PEP005 Topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05%, two day dose
Study: NCT02102789
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
Study: NCT04561219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a day for 5 days
Study: NCT02102789
Drug: HAI
Normalized name: THAIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
Study: NCT02159066
Drug: LGX818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LGX818 and MEK162 (Part I)
Study: NCT02159066
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LGX818 and MEK162 (Part I)
Study: NCT02159066
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LGX818 + MEK162 + LEE011 (Part II)
Study: NCT02159066
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LGX818 + MEK162 + BGJ398 (Part II)
Study: NCT02159066
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LGX818 + MEK162 + BKM120 (Part II)
Study: NCT02159066
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LGX818 + MEK162 + INC280 (Part II)
Study: NCT00153036
Drug: rt-PA 0.9 mg/kg verum or placebo Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00423657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
Study: NCT01040728
Drug: Placebo (for Olodaterol (BI1744)l)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olodaterol low and high dose) delivered by Respimat
Study: NCT01040728
Drug: Placebo (for Tiotropium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Tiotropium 18 mcg) delivered by HandiHaler
Study: NCT02748863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
Study: NCT02138006
Drug: Standard insulin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Mixtard
Study: NCT01231568
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
Study: NCT01231568
Drug: Regimen D
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
Study: NCT02574520
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml once at end of surgery
Study: NCT01353404
Drug: Sequence 1
Normalized name: Antihemophilic Factor (Recombinant) Porcine Sequence 1 U Intravenous Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
Study: NCT01353404
Drug: Sequence 5
Normalized name: antihemophilic factor VIII, recombinant porcine sequence 500 (+/-) unit range INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
Study: NCT03091010
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
Study: NCT03204396
Drug: 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
Study: NCT02557542
Drug: Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous ablation
Study: NCT02314117
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT02314117
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT00523107
Drug: PG2
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG2 500 mg / 500 ml normal saline t.i.w. per week
Study: NCT00523107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml normal saline t.i.w. per week
Study: NCT04189705
Drug: Mucosta Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide 100mg
Study: NCT01611311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
Study: NCT00740194
Drug: Aromatase inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole
Study: NCT00740194
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dermestril
Study: NCT01320358
Drug: ECMPS-IEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECMPS-IEM
Study: NCT01660997
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00901394
Drug: B12-Folic Acid, nitrous oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline.
Study: NCT02244125
Drug: PCD
Normalized name: Eyefull PCD Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: STUDY TREATMENT PHASE: All patients~* 4x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle\]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~* Melphalan 200mg/m2 followed by Autologous Transplantation~* 2x 28 days cycles of PCD, three months post transplantation~Arm B:~* 5x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle\]~MAINTENANCE PHASE: All patients~- Until progression/relapse or discontinuation for any other reason~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle\]
Study: NCT03905525
Drug: CFZ533
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological
Study: NCT00702702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 capsules daily for 3 months
Study: NCT00274248
Drug: MLN518
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02525471
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase.
Study: NCT00984477
Drug: AZD5122
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of oral suspension
Study: NCT00984477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of oral suspension
Study: NCT00984477
Drug: AZD5122
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous infusion
Study: NCT00475670
Drug: Taxane (docetaxel or paclitaxel)
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
Study: NCT03717688
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment
Study: NCT01961505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
Study: NCT04325893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
Study: NCT01665092
Drug: Levo-Carnitine
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01665092
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02994719
Drug: Anti-Parkinson medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
Study: NCT02052908
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03044743
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To modify immune micro-environment
Study: NCT00523757
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00523757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02241148
Drug: Acetaminophen 500mg
Normalized name: ACETAMINOPHEN 500MG CAP
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg, tablets every 8 hours
Study: NCT01814527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 capsules that are identical to the treatment.
Study: NCT00004925
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00420576
Drug: DBT-Danggui Buxue Tang
Normalized name: Buxus sempervirens leafy twig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
Study: NCT03142529
Drug: colon lotion
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
Study: NCT02604446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02604446
Drug: usual pain treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
Study: NCT00275106
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00980330
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
Study: NCT00980330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
Study: NCT00275106
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00275106
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00275106
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00275106
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00275106
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00114816
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01679951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
Study: NCT02920892
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg - 100 mg oral suspension (liquid)
Study: NCT02920892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension (liquid)
Study: NCT00003992
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003992
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01679951
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
Study: NCT03827655
Drug: TAK-954 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-954 placebo-matching intravenous infusion.
Study: NCT00290680
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04527666
Drug: Anticoagulation Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
Study: NCT00864786
Drug: PF03635659
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled doses of 200 mcgQD
Study: NCT00864786
Drug: PF03635659
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled doses of 600 mcg QD
Study: NCT00864786
Drug: PF03635659
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
Study: NCT00935662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, placebo
Study: NCT01043263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily dosing
Study: NCT01518478
Drug: Fluzone® Intradermal (Sanofi Pasteur Inc.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus.
Study: NCT03441204
Drug: LTOT 24 h/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTOT prescribed for 24 h/day.
Study: NCT03441204
Drug: LTOT 15h/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: : LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
Study: NCT02071329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03783754
Drug: telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose combination therapy
Study: NCT03783754
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT01170468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally, daily for 2 years
Study: NCT04778917
Drug: Low-Molecular-Weight Heparins Calcium Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: We use different dose of low-molecular-weight heparins calcium injection to different interventions
Study: NCT01274026
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted.
Study: NCT04553978
Drug: WD-1603
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Study: NCT01667289
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy